Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 239 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Buffered Saline Clear all

Conditions: Zika Virus, Zika Virus Infection, Virus Diseases, Flavivirus Infections, Flaviviral Diseases, Flaviviridae Infections, RNA Virus Infections
Interventions: VRC-ZKADNA090-00-VP, VRC-PBSPLA043-00-VP; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 15 Years to 35 Years
Enrollment: 2,428 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Miami, Florida • Edinburg, Texas • Houston, Texas

Conditions: Shigellosis
Interventions: 240 µg Shigella flexneri 2a Invaplex 50 vaccine, 480 µg Shigella flexneri 2a Invaplex 50 vaccine, 690 Shigella flexneri 2a Invaplex 50 vaccine, Shigella challenge strain; Biological · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 113 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Baltimore, Maryland • Silver Spring, Maryland

Conditions: Moderate or Severe Submental Fullness
Interventions: Deoxycholic acid injection, Placebo; Drug
Lead sponsor: Kythera Biopharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 129 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 10
States / cities: Birmingham, Alabama • Beverly Hills, California • San Francisco, California + 6 more

Conditions: Huntington's Disease
Interventions: VX15/2503, Placebo; Drug
Lead sponsor: Vaccinex Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 29
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 24 more

Conditions: Genital Herpes Simplex Type 2
Interventions: GEN-003 with Matrix M-2, GEN-003, Placebo; Biological
Lead sponsor: Genocea Biosciences, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 7
States / cities: Birmingham, Alabama • Indianapolis, Indiana • Cincinnati, Ohio + 4 more

Conditions: Facet Joint Pain, Back Pain, Inflammation
Interventions: XT-150, Placebo; Biological
Lead sponsor: Xalud Therapeutics, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Napa, California • Santa Monica, California • Winston-Salem, North Carolina

Conditions: Herpes Genitalis
Interventions: VCL-HB01, Phosphate-buffered saline; Biological · Other
Lead sponsor: Vical; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 261 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 15
States / cities: Birmingham, Alabama • San Diego, California • Hollywood, Florida + 12 more

Conditions: Dry Eye, Ocular Inflammation
Interventions: Eye wash; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Moderate to Severe Convexity of Submental Fat, Safety, Efficacy
Interventions: ATX-101, Placebo; Drug
Lead sponsor: Kythera Biopharmaceuticals; Industry
Eligibility: 65 Years to 75 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 6
States / cities: Birmingham, Alabama • Los Angeles, California • Bradenton, Florida + 3 more

Conditions: Osteoarthritis, Knee
Interventions: EUFLEXXA™, placebo; Device
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 588 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Influenza
Interventions: Low dose, Intermediate dose, High dose, Placebo; Biological
Lead sponsor: KBio Inc; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Risk Reduction
Interventions: Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation, Trivalent Salmonella Conjugate Vaccine (TSCV) Half-Strength Formulation, Trivalent Salmonella Conjugate Vaccine (TSCV) Dilutional Half-Strength Formulation, Placebo; Biological · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 49 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Moderate to Severe Convexity of Submental Fat, Safety, Efficacy
Interventions: Deoxycholic Acid, Placebo; Drug
Lead sponsor: Kythera Biopharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 8
States / cities: Newport Beach, California • San Francisco, California • West Hollywood, California + 5 more

Conditions: Non-Proliferative Diabetic Retinopathy
Interventions: Faricimab; Drug
Lead sponsor: Greater Houston Retina Research; Other
Eligibility: 18 Years and older
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 16
States / cities: Bakersfield, California • Modesto, California • Orlando, Florida + 13 more

Conditions: Osteoarthritis, Knee
Interventions: XT-150, Placebo; Biological · Drug
Lead sponsor: Xalud Therapeutics, Inc.; Industry
Eligibility: 45 Years to 85 Years
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 4
States / cities: La Mesa, California • Napa, California • Santa Monica, California + 1 more

Conditions: Influenza
Interventions: Inactivated seasonal influenza vaccine (split virus, Vero cell-derived), Phosphate buffered saline; Biological · Other
Lead sponsor: Alachua Government Services, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 3,670 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 34
States / cities: Tucson, Arizona • Anaheim, California • Sacramento, California + 31 more

Conditions: HPV
Interventions: Gardasil-9, Lidocaine injection, Lorazepam; Biological · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Stem Cell Transplantation, Ventricular Dysfunction, Left
Interventions: Autologous human mesenchymal cells (hMSCs), Autologous human bone marrow cells (hBMCs), Placebo; Biological
Lead sponsor: University of Miami; Other
Eligibility: 21 Years to 90 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Influenza
Interventions: Phosphate Buffered Saline (PBS) diluent, MF59 Adjuvant, H5N1 Antigen; Other · Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 5
States / cities: Atlanta, Georgia • Decatur, Georgia • Iowa City, Iowa + 2 more

Conditions: Atopic Dermatitis
Interventions: S. hominis A 9 Product, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Pneumonia
Interventions: Salmonella Typhi-vectored pneumonia vaccine; Biological
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Persian Gulf Syndrome, Chronic Sinusitis, Fatigue, Acute Sinusitis
Interventions: Nasal Irrigation - Saline, Nasal Irrigation - Xylitol; Other · Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 35 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Cystic Fibrosis
Interventions: Alpha-1 HC 100 mg, Placebo, Alpha-1 HC 200 mg; Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Birmingham, Alabama • Denver, Colorado • Boston, Massachusetts + 3 more

Conditions: Influenza Vaccines, Aged
Interventions: MAS-1 adjuvant and influenza HA antigen, standard dose, inactivated trivalent influenza vaccine (TIV); Biological
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 65 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Palo Alto, California • Iowa City, Iowa • Minneapolis, Minnesota + 1 more

Search by objective public record fields.

VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents

Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection

Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures Study

A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi

Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine

Safety and Efficacy of XT-150 for Facet Joint Osteoarthritis Pain

Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine

Closed Eye Neutrophils in Dry Eye Disease

Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age

A Study of the Efficacy and Safety of EUFLEXXA™ for Treatment of Painful Osteoarthritis of the Knee

Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults

Salmonella Conjugates CVD 2000: Study of Responses to Vaccination With Trivalent Salmonella Conjugate Vaccine to Prevent Invasive Salmonella Disease

Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat

Safety and Efficacy of Faricimab in Patients With NPDR

Efficacy and Safety of XT-150 in Osteoarthritis of the Knee

Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)

HPV Vaccine Reduced Dose

The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)

H5N1 Mix and Match With MF59

Targeted Investigation of Microbiome Elimination

Recombinant Attenuated Salmonella Typhi Vaccine Vectors Producing Streptococcus Pneumoniae PspA

Gulf War Illness Nasal Irrigation Study

Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis

MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly